Why the study?
Does blocking NaV1.8 in the cardiac ganglionated plexi modulate atrial fibrillation inducibility and cardiac conduction in a canine myocardial infarction model?
Does blocking NaV1.8 in the cardiac ganglionated plexi modulate atrial fibrillation inducibility and cardiac conduction in a canine myocardial infarction model?
Blocking NaV1.8 in cardiac ganglionated plexi modulates atrial fibrillation inducibility and cardiac conduction post-myocardial infarction, suggesting a neural regulatory mechanism.
BACKGROUND: 1.8 in the cardiac ganglionated plexi (GP) on the atrial fibrillation inducibility and cardiac conduction in the myocardial infarction model. METHODS: 1.8 blocker A-803,467 (n = 9) or DMSO (n = 9, control) was injected into the four cardiac major GPs. Sinus rate, ventricular rate during atrial fibrillation, PR interval, atrial effective refractory period, atrial fibrillation duration and the cumulative window of atrial vulnerability were measured before and 60 min after A-803,467 injection. RESULTS: 1.8 in canine GPs. CONCLUSIONS: 1.8 in the cardiac GP may modulate atrial fibrillation inducibility and cardiac conduction after myocardial infarction, and the underlying mechanism may be associated with the regulation of the neural activity of the cardiac GP.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: